Login to Your Account



Futility sinks Vertex combo trial in difficult cystic fibrosis subgroup

By Michael Fitzhugh
Staff Writer

Tuesday, August 16, 2016

Vertex Pharmaceuticals Inc. is ending a phase III study testing VX-661 with the company's already-approved Kalydeco (ivacaftor) in a hard-to-treat subgroup of cystic fibrosis patients (CF) after learning that the combination failed to deliver a pre-specified improvement in lung function.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription